CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine

Author's Avatar
May 28, 2018
Article's Main Image

OSLO, Norway and BALTIMORE and GAITHERSBURG, Md., May 27, 2018 (GLOBE NEWSWIRE) -- CEPI—the Coalition for Epidemic Preparedness Innovations—today announced a collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. (NYSE:EBS) under which Profectus and Emergent will receive up to $25 million to advance the development and manufacture of a vaccine against the Nipah virus (NiV), a bat-borne virus that can spread to both humans and livestock.